戻る Agenda
[V7-S2] Use and Application of Real World Data/Evidence Based on Next Generation Medical Infrastructure Act
Session Chair(s)
Shunichi Takahashi, PhD
Director, Head of Open Innovation Center Japan
Bayer Yakuhin, Ltd., Japan
Next Generation Medical Infrastructure Act become effective on 11th May 2018 and we are able to use medical related big data under proper information management. In this session, presenters will share overview of real world data which is being established under all Japan system and important topics of Next Generation Medical Infrastructure Act. In addition, as cases from pharmaceutical company, some presenters will share practices; 1) digital health tool development, 2) data application using EHR (electric health record) or PHR (personal health record). This session will have a time to discuss how should we grow digital health area under all Japan system.
Speaker(s)
Use and Application of Real World Data
Hiroshi Mizushima, PhD
National Institute of Public Health, Japan
Chief Senior Researcher, Center for Public Health Informatics
Overview of Next Generation Medical Infrastructure Act
Haruka Nakada, JD, PhD
National Cancer Center , Japan
Division of Bioethics and Healthcare Law, Center for Public Health Sciences
Our Challenge for Innovation: Real World Data
Masayuki Katsumata
GlaxoSmithKline K.K., Japan
Head, Value Evidence & Outcomes
Value of Real World Evidence to Clinicians
Jovelle Fernandez, MD, PhD
Takeda Pharmaceutical Company Limited, Japan
Vice President, Japan Medical Officer and Head, Japan Medical Affairs
Masakatsu Imoto
Pharmaceuticals and Medical Devices Agency (PMDA), Japan